Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), CVS Health (CVS) and Immunome (IMNM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Staar Surgical (STAA – Research Report), CVS Health (CVS – Research Report) and Immunome (IMNM – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Staar Surgical (STAA)
In a report released today, Adam Maeder from Piper Sandler maintained a Hold rating on Staar Surgical, with a price target of $16.00. The company’s shares closed last Tuesday at $18.92, close to its 52-week low of $13.50.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Staar Surgical with a $22.11 average price target, which is a 18.8% upside from current levels. In a report released today, TipRanks – Google also upgraded the stock to Hold with a $18.00 price target.
See the top stocks recommended by analysts >>
CVS Health (CVS)
In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on CVS Health, with a price target of $98.00. The company’s shares closed last Tuesday at $80.49, close to its 52-week high of $80.75.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $96.24, representing a 18.6% upside. In a report issued on February 20, Deutsche Bank also maintained a Buy rating on the stock.
Immunome (IMNM)
Guggenheim analyst Michael Schmidt maintained a Buy rating on Immunome yesterday and set a price target of $35.00. The company’s shares closed last Tuesday at $21.54.
According to TipRanks.com, Schmidt is a 5-star analyst with an average return of
Currently, the analyst consensus on Immunome is a Strong Buy with an average price target of $36.00, representing a 67.6% upside. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $40.00 price target.
